Oxa-, thia- and diazabicycloalkane derivatives, process for their preparation and their use as pharmaceuticals
申请人:BEECHAM GROUP PLC
公开号:EP0226267A1
公开(公告)日:1987-06-24
Compounds of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
j is 0 or 1;
q is 0, 1 or 2;
p is 0 and r is 2 or 3, or
p is 1 and r is 2;
X is 0, S, SO or NR where R is hydrogen, C1-6 alkyl or C1-10 carboxylic acyl;
Y is NH; or 0 when R, is hydrogen; either R, is C1-6 alkoxy and one of R2, R3 and R4 is hydrogen and the other two are selected from hydrogen, halogen, CF3, C1-6 alkylthio, C1-7 acyl, C1-10 carboxylic acyiamino, C1-6
alkyl S(O)n wherein n is 0, or 2, nitro or amino, aminocarbonyl or aminosulphonyl optionally substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-4 alkyl or phenyl C1-4 alkyl groups any of which phenyl moieties may be substituted by one or two groups selected from halogen, CF3, C1-6 alkyl or C1-6 alkoxy; or R, is hydrogen and R2, R3 and R4 are independently selected from hydrogen; C1-6 alkyl. hydroxy, C1-6 alkoxy, C1-6 alkylthio or halo; or any two on adjacent carbon atoms together are C1-2 alkylenedioxy and the third is hydrogen, C1-6 alkyl, C1-6 alkoxy or halo; one of R5 and R6 is hydrogen, C1-6 alkyl, phenyl or phenyl-C1-6 alkyl, which phenyl moieties may be substituted by C1-6 alkyl, C1-6 alkoxy or haiogen; and the other is hydrogen or C1-6 alkyl; and
R7 is hydrogen, C, alkyl, phenyl or phenyl-C1-3 alkyl, which phenyl moieties may be substituted by C1-6 alkyl, C1-6 alkoxy, CF3 or halogen having gastric motility enhancing activity, anti-emetic activity and/or 5-HT receptor ant. agonist activity, a process and intermediates for their preparation and their use as pharmaceuticals.
式 (I) 的化合物或其药学上可接受的盐:
其中
j 为 0 或 1
q 是 0、1 或 2
p 为 0,r 为 2 或 3,或
p 为 1,r 为 2;
X 是 0、S、SO 或 NR,其中 R 是氢、C1-6 烷基或 C1-10 羧酰基;
当 R 为氢时,Y 为 NH;当 R 为氢时,Y 为 0;当 R 为 C1-6 烷氧基,且 R2、R3 和 R4 中的一个为氢,另两个选自氢、卤素、CF3、C1-6 烷硫基、C1-7 乙酰基、C1-10 羧酰基氨基、C1-6 烷基 S(O)n 时,Y 为 0。
烷基 S(O)n,其中 n 为 0 或 2;硝基或氨基、氨基羰基或氨基磺酰基,可任选被一个或两个选自 C1-6 烷基、C3-8 环烷基、C3-8 环烷基、C3-8 环烷基 C1-4 烷基或苯基 C1-4 烷基的基团取代,其中任何苯基基团可被一个或两个选自卤素、CF3、C1-6 烷基或 C1-6 烷氧基的基团取代;或 R 为氢,R2、R3 和 R4 独立选自氢、C1-6 烷基R5和R6中的一个是氢、C1-6烷基、苯基或苯基-C1-6烷基,其中苯基可被C1-6烷基、C1-6烷氧基或硫代卤素取代;另一个是氢或C1-6烷基。
R7 是氢、C、烷基、苯基或苯基-C1-3 烷基,其中苯基可被 C1-6 烷基、C1-6 烷氧基、CF3 或卤素取代,具有胃动力增强活性、止吐活性和/或 5-HT 受体拮抗剂活性,以及制备它们的工艺和中间体及其作为药物的用途。